26th Feb 2025 17:39
26 February 2025
HALEON PLC
("Haleon" or "the Company")
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BMX86B70
Issuer Name
HALEON PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
Other
Comments
Conversion of American depositary shares into ordinary shares
3. Details of person subject to the notification obligation
Name
Pfizer Inc.
City of registered office (if applicable)
New York
Country of registered office (if applicable)
United States of America
4. Details of the shareholder
Name | City of registered office | Country of registered office |
State Street Nominees Limited | London | United Kingdom |
5. Date on which the threshold was crossed or reached
24-Feb-2025
6. Date on which Issuer notified
26-Feb-2025
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer | |
Resulting situation on the date on which threshold was crossed or reached | 7.310000 | 0.000000 | 7.310000 | 661709764 |
Position of previous notification (if applicable) | 7.310000 | 0.000000 | 7.310000 |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
Ordinary Shares GB00BMX86B70 | 661709764 | 7.310000 | ||
Sub Total 8.A | 661709764 | 7.310000% | ||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
| ||||
Sub Total 8.B1 | ||||
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
| |||||
Sub Total 8.B2 | |||||
9. Information in relation to the person subject to the notification obligation
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
|
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
This notification relates to the conversion by Pfizer Inc. ("Pfizer") of its holding of American depositary shares representing ordinary shares of Haleon plc ("Haleon") into Haleon ordinary shares.These calculations are based on Haleon's issued voting share capital of 9,054,145,714 ordinary shares with voting rights, as communicated by Haleon in its announcement on total voting rights and capital dated 3 February 2025.Pfizer holds its Haleon ordinary shares through State Street Nominees Limited, which holds the legal title to those shares on Pfizer's behalf.
12. Date of Completion
26-Feb-2025
13. Place Of Completion
New York, USA
Amanda Mellor, Company Secretary
Related Shares:
Haleon